GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Astec Lifesciences Ltd (NSE:ASTEC) » Definitions » EBIT

Astec Lifesciences (NSE:ASTEC) EBIT : ₹-937 Mil (TTM As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Astec Lifesciences EBIT?

Astec Lifesciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ₹-152 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹-937 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Astec Lifesciences's annualized ROC % for the quarter that ended in Dec. 2024 was -12.64%. Astec Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -8.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Astec Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -4.86%.


Astec Lifesciences EBIT Historical Data

The historical data trend for Astec Lifesciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astec Lifesciences EBIT Chart

Astec Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 739.47 938.22 1,298.21 551.06 -368.92

Astec Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -261.25 53.80 -545.97 -292.06 -152.28

Competitive Comparison of Astec Lifesciences's EBIT

For the Agricultural Inputs subindustry, Astec Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astec Lifesciences's EV-to-EBIT Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Astec Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Astec Lifesciences's EV-to-EBIT falls into.


;
;

Astec Lifesciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-937 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astec Lifesciences  (NSE:ASTEC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Astec Lifesciences's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-685.72 * ( 1 - -60.52% )/( (8707.296 + 0)/ 1 )
=-1100.717744/8707.296
=-12.64 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8820.968 - 807.199 - ( 27.857 - max(0, 3741.905 - 3048.378+27.857))
=8707.296

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Astec Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-609.136/( ( (5201.749 + max(2110.496, 0)) + (0 + max(0, 0)) )/ 1 )
=-609.136/( ( 7312.245 + 0 )/ 1 )
=-609.136/7312.245
=-8.33 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1304.008 + 1498.352 + 190.444) - (807.199 + 0 + 75.109)
=2110.496

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Astec Lifesciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-936.517/19287.695
=-4.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astec Lifesciences EBIT Related Terms

Thank you for viewing the detailed overview of Astec Lifesciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Astec Lifesciences Business Description

Traded in Other Exchanges
Address
Eastern Express Highway, Godrej One, 3rd Floor, Pirojshanagar, Vikhroli (East), Mumbai, MH, IND, 400 079
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.

Astec Lifesciences Headlines

No Headlines